Sponsored by

Chimerix

Please click on the above banner for more details

WEBSITECHANGES

You can Subscribe to our RSS FEED: which delivers brain tumor news and additions to the website via RSS.

Click HERE for details on RSS.

Displaying items 326 to 350 of about 5882

Previous 25

Website Changes

04/24/2023

Gel has 100% success rate in stopping brain tumors in mice

04/24/2023

The Uncertainty of Clinical Trial Results

04/21/2023

Oblato Announces the First Enrollment in a Phase 1 Clinical Trial for an Oral Formulation of OKN-007 in Recurrent High-Grade Glioma Patients in the USA

04/21/2023

FDA About to Make Drug Approvals More Difficult

04/18/2023

UCLA BRAIN TUMOR CENTER TO HOST 23RD ANNUAL UCLA BRAIN TUMOR CONFERENCE

04/18/2023

Survey for Community Neuro-oncs!

04/14/2023

New TSA Protocol For Optune Users in US Airports

04/13/2023

From Tragedy to Triumph: A Promising New Treatment for Pediatric Brain Cancer

04/11/2023

Special diet triggers self-destruction of brain cancer cells in mice

04/11/2023

Meet actual users and caregivers at an Optune® Open House (Depew, NY)

04/06/2023

Musella Foundation Copay Program now closed to new and renewal patients

04/02/2023

Musella Foundation Copay Program Almost Closed!

03/31/2023

Recombinant polio–rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial

03/28/2023

Apogenix’ Partner CANbridge Announces 67 % Five-Year Overall Survival Rate Compared to 8.2 % in Institutional Database With Asunercept Plus Standard of Care in Newly Diagnosed Glioblastoma Multiforme

03/28/2023

Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5

03/24/2023

The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models

03/17/2023

FDA Approves Dabrafenib Plus Trametinib for Pediatric BRAF V600E-Mutant Low-Grade Glioma

03/15/2023

Servier`s Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)

03/15/2023

Drug offers renewed hope to brain cancer patients

03/15/2023

Hoops For Hannah Brackets Deadline

03/13/2023

Head to the Hill 2023

03/12/2023

Newly-diagnosed high grade glioma surgery with carmustine wafers implantation. A long-term nationwide retrospective study

03/12/2023

Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas

03/08/2023

Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France

03/08/2023

Weil Cornell Medicine webinars on Advances in Brain Tumor Research and Treatments

Our privacy / cookie policy has changed.
Click HERE to read it!